Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Change in Receivables (2023 - 2025)

Iovance Biotherapeutics has reported Change in Receivables over the past 3 years, most recently at $15.7 million for Q4 2025.

  • Quarterly results put Change in Receivables at $15.7 million for Q4 2025, up 15.58% from a year ago — trailing twelve months through Dec 2025 was $13.1 million (down 81.05% YoY), and the annual figure for FY2025 was $13.1 million, down 81.05%.
  • Change in Receivables for Q4 2025 was $15.7 million at Iovance Biotherapeutics, up from $6.8 million in the prior quarter.
  • Over the last five years, Change in Receivables for IOVA hit a ceiling of $31.4 million in Q2 2024 and a floor of -$11.0 million in Q2 2025.
  • Median Change in Receivables over the past 3 years was $1.6 million (2025), compared with a mean of $7.5 million.
  • Biggest five-year swings in Change in Receivables: surged 94960.61% in 2024 and later tumbled 135.07% in 2025.
  • Iovance Biotherapeutics' Change in Receivables stood at $149000.0 in 2023, then skyrocketed by 9008.72% to $13.6 million in 2024, then grew by 15.58% to $15.7 million in 2025.
  • The last three reported values for Change in Receivables were $15.7 million (Q4 2025), $6.8 million (Q3 2025), and -$11.0 million (Q2 2025) per Business Quant data.